GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » Beneish M-Score

LENSAR (LENSAR) Beneish M-Score : -2.77 (As of May. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is LENSAR Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.77 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for LENSAR's Beneish M-Score or its related term are showing as below:

LNSR' s Beneish M-Score Range Over the Past 10 Years
Min: -2.81   Med: -2.77   Max: -2.39
Current: -2.77

During the past 5 years, the highest Beneish M-Score of LENSAR was -2.39. The lowest was -2.81. And the median was -2.77.


LENSAR Beneish M-Score Historical Data

The historical data trend for LENSAR's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR Beneish M-Score Chart

LENSAR Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -2.39 -2.81 -2.77

LENSAR Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.81 -2.21 -1.98 -2.31 -2.77

Competitive Comparison of LENSAR's Beneish M-Score

For the Medical Devices subindustry, LENSAR's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENSAR's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where LENSAR's Beneish M-Score falls into.



LENSAR Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of LENSAR for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5811+0.528 * 1.1274+0.404 * 0.7896+0.892 * 1.1925+0.115 * 1.0979
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8056+4.679 * -0.036933-0.327 * 0.7843
=-2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $4.32 Mil.
Revenue was 12.105 + 9.795 + 12.012 + 8.252 = $42.16 Mil.
Gross Profit was 5.149 + 4.877 + 6.761 + 4.32 = $21.11 Mil.
Total Current Assets was $46.44 Mil.
Total Assets was $69.59 Mil.
Property, Plant and Equipment(Net PPE) was $8.14 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.52 Mil.
Selling, General, & Admin. Expense(SGA) was $26.10 Mil.
Total Current Liabilities was $11.63 Mil.
Long-Term Debt & Capital Lease Obligation was $1.75 Mil.
Net Income was -3.926 + 2.568 + -8.753 + -4.272 = $-14.38 Mil.
Non Operating Income was -0.965 + 4.608 + -5.886 + 0.089 = $-2.15 Mil.
Cash Flow from Operations was -0.48 + -0.339 + -2.144 + -6.696 = $-9.66 Mil.
Total Receivables was $6.24 Mil.
Revenue was 10.232 + 7.748 + 8.038 + 9.34 = $35.36 Mil.
Gross Profit was 6.482 + 3.889 + 4.892 + 4.692 = $19.96 Mil.
Total Current Assets was $33.72 Mil.
Total Assets was $55.84 Mil.
Property, Plant and Equipment(Net PPE) was $6.88 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.41 Mil.
Selling, General, & Admin. Expense(SGA) was $27.17 Mil.
Total Current Liabilities was $11.42 Mil.
Long-Term Debt & Capital Lease Obligation was $2.27 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.324 / 42.164) / (6.24 / 35.358)
=0.102552 / 0.176481
=0.5811

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(19.955 / 35.358) / (21.107 / 42.164)
=0.56437 / 0.500593
=1.1274

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (46.444 + 8.138) / 69.585) / (1 - (33.716 + 6.879) / 55.844)
=0.215607 / 0.273064
=0.7896

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=42.164 / 35.358
=1.1925

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.406 / (3.406 + 6.879)) / (3.515 / (3.515 + 8.138))
=0.331162 / 0.301639
=1.0979

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(26.1 / 42.164) / (27.17 / 35.358)
=0.619011 / 0.768426
=0.8056

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.75 + 11.632) / 69.585) / ((2.272 + 11.421) / 55.844)
=0.192312 / 0.245201
=0.7843

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-14.383 - -2.154 - -9.659) / 69.585
=-0.036933

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

LENSAR has a M-score of -2.77 suggests that the company is unlikely to be a manipulator.


LENSAR (LENSAR) Business Description

Traded in Other Exchanges
N/A
Address
2800 Discovery Drive, Orlando, FL, USA, 32826
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer director, 10 percent owner NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis director, 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc 10 percent owner 62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii officer: Chief Financial Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong officer: Principal Accounting Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton officer: Chief Operating Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis director, officer: Chief Executive Officer C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc. 10 percent owner 59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391